EYPT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EY

Mkt Cap

$257.3M

Volume

2.37M

Next Earnings

November 4th

Loading chart

EY

EYPTEyePoint, Inc. Common Stock

EYPT

Pay with—

Available Balance0.00

EY

Mkt Cap

$270.7M

Volume

2.37M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Here's Why You Should Add EYPT Stock to Your Portfolio NowEyePoint (EYPT) reported mixed results from its LUGANO wet AMD study, with Duravyu failing to meet the primary endpoint but showing encouraging secondary endpoint results. The company expects LUCIA study data in Q4 2026 and has completed enrollment in two phase III DME studies with results expected in Q4 2027. EYPT shares have declined 83.5% year-to-date despite a Zacks Rank #2 (Buy) rating.Zacks Investment Research · Oct 15, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.GlobeNewswire Inc. · Oct 6, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the company's announcement on August 17, 2026, that its DURAVYU drug failed to meet primary endpoints in the LUGANO Phase 3 clinical trial for wet AMD treatment. The failure to demonstrate superiority over Regeneron's Eylea resulted in a 66.98% stock price decline, falling from approximately $14.75 to $4.87 per share.GlobeNewswire Inc. · Sep 8, 2026

EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law FirmEyePoint Inc. (NASDAQ: EYPT) announced disappointing Phase 3 clinical trial results for DURAVYU on August 17, 2026, failing to meet its primary endpoint in the LUGANO trial for wet age-related macular degeneration treatment. The stock subsequently dropped over 66%, prompting a securities litigation investigation by KTMC on behalf of affected investors.GlobeNewswire Inc. · Sep 4, 2026

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific MeetingEyePoint, Inc. (EYPT) announced its participation in three major investor conferences in September 2026, including Citi Biopharma, Cantor Global Healthcare, and Morgan Stanley Global Healthcare conferences. The company will also present multiple scientific presentations at The Retina Society's 59th Annual Scientific Meeting, focusing on its lead product candidate DURAVYU (vorolanib intravitreal insert) for retinal diseases, including Phase 3 trial data for wet AMD treatment.GlobeNewswire Inc. · Sep 2, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)EyePoint, Inc. granted non-statutory stock options to three new employees as inducement awards on June 15, 2026. The company granted options to purchase 39,700 shares at an exercise price of $12.08 per share with a ten-year term and four-year vesting schedule. The grants were approved by the Compensation Committee in accordance with NASDAQ regulations.GlobeNewswire Inc. · Jun 16, 2026

EyePoint Announces Participation at Upcoming Investor ConferencesEyePoint, Inc. (EYPT) announced participation in three upcoming healthcare conferences in May-June 2026. The company also reported a third consecutive positive Data Safety Monitoring Committee (DSMC) recommendation for its Phase 3 wet AMD trials of DURAVYU™, with topline data expected in mid-2026. The trials continue to show a favorable safety profile.GlobeNewswire Inc. · May 19, 2026

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate DevelopmentsEyePoint announced Q1 2026 financial results with $223 million in cash runway extending into Q4 2027. The company's lead product DURAVYU is progressing through Phase 3 trials for wet AMD and DME, with topline data expected beginning mid-2026 for wet AMD and Q4 2027 for DME. However, net revenue declined significantly to $0.7 million from $24.5 million year-over-year, while operating expenses increased to $87.9 million, resulting in a net loss of $84.8 million.GlobeNewswire Inc. · May 6, 2026

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last QuarterCormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.The Motley Fool · Mar 16, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)EyePoint, Inc. (Nasdaq: EYPT) granted non-statutory stock options to purchase 20,000 shares of common stock to six new employees as inducement awards on March 13, 2026, with an exercise price of $13.20 per share. The options vest over four years with a ten-year term. The company continues advancing its lead product DURAVYU in Phase 3 trials for wet AMD and DME, with topline data expected beginning in mid-2026 for wet AMD.GlobeNewswire Inc. · Mar 16, 2026

to start trading

EY

EYPTEyePoint, Inc. Common Stock

EYPT

Pay with—

Available Balance0.00

Your PositionYou don't own any EYPT yet.

Related Tickers

Earnings